Cefotaxime: Difference between revisions
m (Protected "Cefotaxime": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 19: | Line 19: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Cefotaxime''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[kɛfəˈtæksim, sɛfə-]}}) is a third-generation [[cephalosporin]] [[antibiotic]]. Like other third-generation cephalosporins, it has broad spectrum activity against [[Gram positive]] and [[Gram negative]] [[bacteria]]. In most cases, it is considered to be equivalent to [[ceftriaxone]] in terms of safety and efficacy. '''Cefotaxime sodium''' is marketed under various trade names including '''Claforan''' ([[Sanofi-Aventis]]). | '''Cefotaxime''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[kɛfəˈtæksim, sɛfə-]}}) is a third-generation [[cephalosporin]] [[antibiotic]]. Like other third-generation cephalosporins, it has broad spectrum activity against [[Gram positive]] and [[Gram negative]] [[bacteria]]. In most cases, it is considered to be equivalent to [[ceftriaxone]] in terms of safety and efficacy. '''Cefotaxime sodium''' is marketed under various trade names including '''Claforan''' ([[Sanofi-Aventis]]). | ||
| Line 48: | Line 48: | ||
==References== | ==References== | ||
1. http://www.merck.com/mmpe/lexicomp/cefotaxime.html | 1. http://www.merck.com/mmpe/lexicomp/cefotaxime.html | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WS}} | {{WS}} | ||
Revision as of 23:36, 8 August 2012
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Metabolism | Hepatic |
| Elimination half-life | 0.8–1.4 hours |
| Excretion | 50–85% renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H17N5O7S2 |
| Molar mass | 455.47 g/mol |
|
WikiDoc Resources for Cefotaxime |
|
Articles |
|---|
|
Most recent articles on Cefotaxime |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cefotaxime at Clinical Trials.gov Clinical Trials on Cefotaxime at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cefotaxime
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cefotaxime Discussion groups on Cefotaxime Patient Handouts on Cefotaxime Directions to Hospitals Treating Cefotaxime Risk calculators and risk factors for Cefotaxime
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cefotaxime |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Cefotaxime (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.[1]
Clinical use
Treatment of susceptible infection in respiratory tract, skin and skin structure, bone and joint, urinary tract, gynecologic as well as septicemia, and documented or suspected meningitis. Active against most gram-negative bacilli (not Pseudomonas) and gram-positive cocci (not enterococcus). Active against many penicillin-resistant pneumococci[2]. Also see
Chemistry
The syn-configuration of the methoxyimino moiety confers stability to β-lactamase enzymes produced by many Gram-negative bacteria. Such stability to β-lactamases increases the activity of cefotaxime against otherwise resistant Gram-negative organisms.
External links
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Cephalosporin antibiotics